STREAM is a collaboration of researchers who share a common set of principles about the goals and methods for studying clinical translation. We apply empirical and philosophical tools for addressing scientific, ethical, and policy challenges in the development and translation of health technologies. Our members work in ethics, epidemiology, biology, psychology, and various medical specialties. The network is centered at McGill University, and has affiliates throughout North America and abroad.
STREAM is inviting applications for a postdoctoral research fellow with a background in research ethics, epidemiology, biostatistics, or meta-research.
See here for more details on the position and application process.
Feustel AC, MacPherson A, Fergusson DA, Kieburtz K, Kimmelman J. Risks and benefits of unapproved, disease-modifying treatments for neurodegenerative disease. Neurology. December 2, 2019.
Rezak M, de Carvalho M. Disease modification in neurodegenerative diseases: Not quite there yet. Neurology. December 2, 2019.
Sarvas H, Carlisle B, Dolter S, Vinarov E, Kimmelman J. Impact of Precision Medicine on Efficiencies of Novel Drug Development in Cancer. Journal of the National Cancer Institute. November 13, 2019.
Carlisle BG, Zheng T, Kimmelman J. Imatinib and the long tail of targeted drug development. Nature Reviews Clinical Oncology. October 24, 2019.
Doussau A, Vinarov E, Barsanti-Innes B, Kimmelman J. Comparison between protocols and publications for prognostic and predictive cancer biomarker studies. Clinical Trials. October 5, 2019.
Carlisle BG, Doussau A, Kimmelman J. Benefit, burden, and impact for a cohort of post-approval cancer combination trials. Clinical Trials. October 3, 2019.
Kimmelman J. Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine. Nature Reviews Clinical Oncology. August 30, 2019.
London AJ, Kimmelman J. Clinical Trial Portfolios: A Critical Oversight in Human Research Ethics, Drug Regulation, and Policy. Hastings Center Report. August 20, 2019.
In Hunting for Cures, Ethics Can Strengthen Clinical Trials. Carnegie Mellon News. November 6, 2019.
MacPherson A, Kimmelman J. Ethical development of stem-cell-based interventions. Nature Medicine. July 3, 2019.
Pratte M, Ganeshamoorthy S, Carlisle B, Kimmelman J. How well are Phase 2 cancer trial publications supported by preclinical efficacy evidence? International Journal of Cancer. May 14, 2019.
Federico C, Wang T, Doussau A, Mogil J, Fergusson D, Kimmelman J. Assessment of Pregabalin Postapproval Trials and the Suggestion of Efficacy for New Indications: A Systematic Review. JAMA Internal Medicine. January 1, 2019.
When Clinical Trials Are Marketing Ploys, Not Science. Forbes. November 28, 2018.
Unconfirmed exploratory trials after approvals may cause too much off-label prescribing. STAT News. December 12, 2018.
Jonathan Kimmelman quoted in Nature on placebo-controlled clinical trials for regenerative medicine in an article on Japan's regulation of cell-based interventions.
Jonathan Kimmelman quoted in Nature on the use of registries for preclinical trials.
Jonathan Kimmelman quoted in Chemistry World on the hype surrounding unproven stem-cell based interventions.
Jonathan Kimmelman quoted in Bloomberg on the ethics of genetic medicine.
Jonathan Kimmelman quoted in STAT News on a study of a diagnostic cancer test published with missing data.
STAT News and Forbes cover research published by doctoral candidate Carole Federico and Jonathan Kimmelman on how post-approval exploratory trials can influence off-label prescribing.